Michael W. Straza, MD/PhD

Hence why people don’t trust science or MDs anymore. We have a doctor you posted likely paid saying they violated national guidelines for what payers deem experimental, we have biomedical news agencies funded by industry saying these devices are amazing for things they are not approved for, we have major medical meetings promoting these devices, we even have @nytimes articles saying how great these devices are. Yet reality is there is not a single well done multi center randomized trial with reasonable endpoints and good followup showing it is better than AS or RT. To be clear, none of this is targeting the Vanquish system. It is the whole field of ablative devices being used for cancer without being approved for cancer.

@marklewismd Friday me does this to Monday me every week

Turns out last Friday me was writing to-do lists this Monday me can’t cash

@joshuapalmermd @DrAMansouri Agree, no shortage of need. Radiographic localization of a sensitive emitter would inform a lot of the debate around margins, both upfront and in recurrence.

@DrAMansouri Very cool, lots of room in this space, what theranostic molecule are they using? A beta emitter? Alpha?

🚨 Exciting news on the horizon for glioblastoma fighters! Danish company Curasight is gearing up to launch a Phase 1 trial for uTREAT, their targeted radiopharmaceutical, likely starting in Europe Q4 2025. Full details pending EMA green light. 🧠💉 uPAR is a protein that's overproduced in about 94% of high-grade gliomas like GBM, making tumors more aggressive and invasive. Theranostics? It's like a smart combo: Use imaging (uTRACE) to spot the cancer, then zap it precisely with therapy (uTREAT). 🔍⚡ Why better than standard radiation? This delivers radiation right inside the tumor cells, sparing healthy brain tissue and potentially cutting side effects. 🎯 Phase 1 trials are the first step in humans—focusing on safety, right dose, and early signs it works. uTREAT aims to prove it's safe for newly diagnosed GBM patients post-surgery. Stay tuned! #Glioblastoma #BrainCancer #Theranostics @theABTA @NBTStweets @glioblastomaorg @EANOassociation @WeTrialshub @MansouriMDLab

@SprakerMDPhD @NiuSanford As if on cue: redjournal.org/article/S0360-… @RonaldChenMD

@joshuapalmermd @ASTRO_org @ESTRO_RT @NeuroOnc @HaleyPerlow @OhioStateRadOnc Also impressive work, character limit forces one to trim the niceties.

@joshuapalmermd @ASTRO_org @ESTRO_RT @NeuroOnc @HaleyPerlow @OhioStateRadOnc What portion of these were treated outpatient versus inpatient? Logistics of SRS and OR time and all preradiosurgical/surgical planning has been biggest barrier to making this routine. I see the median time from SRS to surgery was 1 day, but how long from diagnosis to SRS?

Excited to see our massive preop vs post op SRT data out for brain metastasis in the Red Journal. Over 450 patients we show preop SRT significantly lowers nLMD, LF and RN. @ASTRO_org @ESTRO_RT @NeuroOnc @HaleyPerlow @OhioStateRadOnc redjournal.org/article/S0360-…

COMEBACK COMPLETE!!!!!!!!!!!!!!!!!!!!!!!!!!!

@DrChowdharyMD @ProtonStorey @drmattmc Adaptive therapy probably should be the purview of full time clinicians rather than creating a new source of labor.

@marklewismd Welcome to our fair city

Normalize recombobulation

@marklewismd If this isn’t always 4:30 on a Friday

When the radiologist calls and wants to speak to you urgently

@SeanFennessey The rare successful reverse jinx

Riegel et al. @BrittaBureauMD @MedicalCollege analyzed real-world outcomes for newly diagnosed GBM patients treated with or without TTFields and found that TTFields improved OS and PFS, with higher device usage linked to better outcomes. #JNO Read more:link.springer.com/article/10.100…

2 years since we saw this man healthy in the playoffs. #letsgoBucks

RT if you love Giannis Antetokounmpo.

@nathanmarzion 2 clutch blocks to boot

Giannis Antetokounmpo's last 6 games: 32 PTS / 11 REB / 15 AST / +22 28 PTS / 11 REB / 5 AST / +6 23 PTS / 13 REB / 10 AST / +26 36 PTS / 15 REB / 10 AST / +17 35 PTS / 17 REB / 20 AST / +23 37 PTS / 5 REB / 11 AST / +23

@joshuapalmermd Up is down, right is left. It is hard to tell how many patients with poor prognosis were filtered out via eligibility and binning in cohort C, but given the modest study size, and no direct comparison to standard of care for brain mets I can’t say this should change anything

Is it just me or is the interpretation strange for this study, best ORR was 51% and they say it’s the SOC and SRS should be investigated? SRS has excellent and durable control for brain metastasis and was already the SOC. thelancet.com/journals/lanon…

@cwspeers @UMichRadOnc @RadOncUH @DrSpratticus @UABmedphys @UABradonc Congratulations and good luck!

Couldn’t be more grateful for amazing colleagues and mentors @UMichRadOnc and @RadOncUH and especially @DrSpratticus. Incredibly humbled and honored to join amazing groups @UABmedphys @UABradonc . Excited for what the future holds for the department, school, community, and field!

Now tell me who the real MVP is

Congratulations to Dr. @whallradonc on being named the next Chair for @MCWRadOnc! We are so fortunate to have him as our next leader. I look forward to working with him to advance @MedicalCollege and @MCWCancerCenter's impact in cancer care and beyond.